Unexpected hypereosinophilia after Sinopharm vaccination: a case report.

ABSTRACT:

Background

COVID-19 vaccines have been pivotal in the management of the recent pandemic. However, despite their safety and efficacy, apprehension regarding possible adverse effects has always been raised. Most of the vaccine-related side effects are mild. However, serious complications like anaphylaxis and thromboembolic events have also been reported. Various hematological disorders, including hypereosinophilia, have been reported following COVID-19 vaccination, the exact mechanisms of which remain unclear.

Case presentation

We report a 66-year-old male who developed hypereosinophilia (absolute eosinophil count: 4063 cells/µL) and lymphadenopathy two months after receiving the third dose of the BBIBP-CorV (Sinopharm) COVID-19 vaccine. Extensive investigations failed to iden

SUBMITTER: Dalfardi B 

PROVIDER: S-EPMC12016119 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature